Single dose of inactivated Japanese encephalitis vaccine with poly(γ-glutamic acid) nanoparticles provides effective protection from Japanese encephalitis virus

Vaccine

Volumn 26, Issue 5, 2008, Pages 589-594

  Okamoto, Shigefumi ^a   Yoshii, Hironori ^a,b   Ishikawa, Toyokazu ^b   Akagi, Takami ^b,c   Akashi, Mitsuru ^b,c   Takahashi, Michiaki ^d   Yamanishi, Koichi ^a   Mori, Yasuko ^a  

^a NATIONAL INSTITUTE OF BIOMEDICAL INNOVATION   (Japan)

^b OSAKA UNIVERSITY   (Japan)

^c JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^d Osaka University   (Japan)

Author keywords

Adjuvant; Japanese encephalitis virus (JEV); Poly( glutamic acid) nanoparticles ( PGA NPs); Single dose immunization

Indexed keywords

ALUMINUM POTASSIUM SULFATE; JAPANESE ENCEPHALITIS VACCINE; POLY(GAMMA GLUTAMIC ACID); POLYGLUTAMIC ACID; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIODEGRADABILITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; EPIDEMIC ENCEPHALITIS; FEMALE; IMMUNIZATION; JAPANESE ENCEPHALITIS VIRUS; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SINGLE DRUG DOSE; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; DRUG EVALUATION, PRECLINICAL; ENCEPHALITIS, JAPANESE; FEMALE; IMMUNIZATION; IMMUNIZATION SCHEDULE; INJECTIONS, INTRAPERITONEAL; JAPANESE ENCEPHALITIS VACCINES; MICE; MICE, INBRED BALB C; NANOPARTICLES; POLYGLUTAMIC ACID; VACCINES, INACTIVATED;

EID: 37849044191     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.11.067     Document Type: Article

References (38)

1. Kurane I., and Takasaki T. Immunogenicity and protective efficacy of the current inactivated Japanese encephalitis vaccine against different Japanese encephalitis virus strains. Vaccine 18 Suppl 2 (2000) 33-35
2. Mackenzie J.S., Chua K.B., Daniels P.W., Eaton B.T., Field H.E., Hall R.A., et al. Emerging viral diseases of Southeast Asia and the Western Pacific. Emerg Infect Dis 7 3 Suppl (2001) 497-504
3. Mackenzie J.S., Johansen C.A., Ritchie S.A., van den Hurk A.F., and Hall R.A. Japanese encephalitis as an emerging virus: the emergence and spread of Japanese encephalitis virus in Australasia. Curr Top Microbiol Immunol 267 (2002) 49-73
4. Solomon T., and Mallewa M. Dengue and other emerging flaviviruses. J Infect 42 2 (2001) 104-115
5. Gubler D.J., Kuno G., Markoff, and Flaviviruses L. In: Knipe D.M., Howley P.M., Griffin D.E., Martin M.A., Ramb R.A., Roizman B., and Straus S.E. (Eds). Fields virology. Fifth edition (2007), Lippincott-Raven, Philadelphia, PA 1153-1252
6. Mori Y., Okabayashi T., Yamashita T., Zhao Z., Wakita T., Yasui K., et al. Nuclear localization of Japanese encephalitis virus core protein enhances viral replication. J Virol 79 6 (2005) 3448-3458
7. Leder K., Weller P.F., and Wilson M.E. Travel vaccines and elderly persons: review of vaccines available in the United States. Clin Infect Dis 33 9 (2001) 1553-1566
8. Shlim D.R., and Solomon T. Japanese encephalitis vaccine for travelers: exploring the limits of risk. Clin Infect Dis 35 2 (2002) 183-188
9. Infectious Diseases Surveillance Center. Immunization schedule, Japan 2005 (July 29). Available from: http://idsc.nih.go.jp/vaccine/dschedule/ImmEN_050729rev.gif.
10. Bista M.B., Banerjee M.K., Shin S.H., Tandan J.B., Kim M.H., Sohn Y.M., et al. Efficacy of single-dose SA 14-14-2 vaccine against Japanese encephalitis: a case-control study. Lancet 358 9284 (2001) 791-795
11. Ohrr H., Tandan J.B., Sohn Y.M., Shin S.H., Pradhan D.P., and Halstead S.B. Effect of single dose of SA 14-14-2 vaccine 1 year after immunisation in Nepalese children with Japanese encephalitis: a case-control study. Lancet 366 9494 (2005) 1375-1378
12. Petrovsky N., and Aguilar J.C. Vaccine adjuvants: current state and future trends. Immunol Cell Biol 82 5 (2004) 488-496
13. Uto T., Wang X., Sato K., Haraguchi M., Akagi T., Akashi M., et al. Targeting of antigen to dendritic cells with poly(gamma-glutamic acid) nanoparticles induces antigen-specific humoral and cellular immunity. J Immunol 178 5 (2007) 2979-2986
14. Akagi T., Higashi M., Kaneko T., Kida T., and Akashi M. In vitro enzymatic degradation of nanoparticles prepared from hydrophobically-modified poly(gamma-glutamic acid). Macromol Biosci 5 7 (2005) 598-602
15. Akagi T., Kaneko T., Kida T., and Akashi M. Preparation and characterization of biodegradable nanoparticles based on poly(gamma-glutamic acid) with l-phenylalanine as a protein carrier. J Control Release 108 2/3 (2005) 226-236
16. Akagi T., Kaneko T., Kida T., and Akashi M. Multifunctional conjugation of proteins on/into bio-nanoparticles prepared by amphiphilic poly(gamma-glutamic acid). J Biomater Sci Polym Ed 17 8 (2006) 875-892
17. Akagi T., Wang X., Uto T., Baba M., and Akashi M. Protein direct delivery to dendritic cells using nanoparticles based on amphiphilic poly(amino acid) derivatives. Biomaterials 28 23 (2007) 3427-3436
18. Kaneko T., Higashi M., Matsusaki M., Akagi T., and Akashi M. Self-assembled soft nanofibrils of amphipathic polypeptides and their morphological transformation. Chem Mater 17 (2005) 2484-2486
19. Matsusaki M., Hiwatari K.-I., Higashi M., Kaneko T., and Akashi M. Stably-dispersed and surface-functional bionanoparticles prepared by self-assembling amphipathic polymers of hydrophilic poly(gamma-glutamic acid) bearing hydrophobic amino acids. Chem Lett 33 (2004) 398-399
20. Srivastava A.K., Putnak J.R., Lee S.H., Hong S.P., Moon S.B., Barvir D.A., et al. A purified inactivated Japanese encephalitis virus vaccine made in Vero cells. Vaccine 19 31 (2001) 4557-4565
21. Kojima A., Yasuda A., Asanuma H., Ishikawa T., Takamizawa A., Yasui K., et al. Stable high-producer cell clone expressing virus-like particles of the Japanese encephalitis virus e protein for a second-generation subunit vaccine. J Virol 77 16 (2003) 8745-8755
22. Badovinac V.P., Messingham K.A., Jabbari A., Haring J.S., and Harty J.T. Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination. Nat Med 11 7 (2005) 748-756
23. Iwasaki A., and Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 5 10 (2004) 987-995
24. Luci C., Hervouet C., Rousseau D., Holmgren J., Czerkinsky C., and Anjuere F. Dendritic cell-mediated induction of mucosal cytotoxic responses following intravaginal immunization with the nontoxic B subunit of cholera toxin. J Immunol 176 5 (2006) 2749-2757
25. Wang X., Uto T., Akagi T., Akashi M., and Baba M. Induction of potent CD8+ T-cell responses by novel biodegradable nanoparticles carrying human immunodeficiency virus type 1 gp120. J Virol 81 18 (2007) 10009-10016
26. Okamoto S., Yoshii H., Akagi T., Akashi M., Ishikawa T., Okuno Y., et al. Influenza hemagglutinin vaccine with poly(gamma-glutamic acid) nanoparticles enhances the protection against influenza virus infection through both humoral and cell-mediated immunity. Vaccine 25 49 (2007) 8270-8278
27. HogenEsch H. Mechanisms of stimulation of the immune response by aluminum adjuvants. Vaccine 20 Suppl 3 (2002) S34-S39
28. Zoeteweij J.P., Epperson D.E., Porter J.D., Zhang C.X., Frolova O.Y., Constantinides A.P., et al. GM1 binding-deficient exotoxin is a potent noninflammatory broad spectrum intradermal immunoadjuvant. J Immunol 177 2 (2006) 1197-1207
29. Hollosi M., Shen Z.M., Perczel A., and Fasman G.D. Stable intrachain and interchain complexes of neurofilament peptides: a putative link between Al3+ and Alzheimer disease. Proc Natl Acad Sci USA 91 11 (1994) 4902-4906
30. Spink D. Aluminum and Alzheimer's disease. CMAJ 146 4 (1992) 431 [author reply 32]
31. Verstraeten S.V., Keen C.L., Golub M.S., and Oteiza P.I. Membrane composition can influence the rate of Al3+-mediated lipid oxidation: effect of galactolipids. Biochem J 333 Pt 3 (1998) 833-838
32. Davenport F.M., Hennessy A.V., and Askin F.B. Lack of adjuvant effect of A1PO4 on purified influenza virus hemagglutinins in man. J Immunol 100 5 (1968) 1139-1140
33. Eriksson A.M., Schon K.M., and Lycke N.Y. The cholera toxin-derived CTA1-DD vaccine adjuvant administered intranasally does not cause inflammation or accumulate in the nervous tissues. J Immunol 173 5 (2004) 3310-3319
34. Ohmura M., Yamamoto M., Kiyono H., Fujihashi K., Takeda Y., and McGhee J.R. Highly purified mutant E112K of cholera toxin elicits protective lung mucosal immunity to diphtheria toxin. Vaccine 20 5/6 (2001) 756-762
35. Kurane I. Immune responses to Japanese encephalitis virus. Curr Top Microbiol Immunol 267 (2002) 91-103
36. Konishi E., Ajiro N., Nukuzuma C., Mason P.W., and Kurane I. Comparison of protective efficacies of plasmid DNAs encoding Japanese encephalitis virus proteins that induce neutralizing antibody or cytotoxic T lymphocytes in mice. Vaccine 21 25/26 (2003) 3675-3683
37. Konishi E., Yamaoka M., Khin Sane W., Kurane I., Takada K., and Mason P.W. The anamnestic neutralizing antibody response is critical for protection of mice from challenge following vaccination with a plasmid encoding the Japanese encephalitis virus premembrane and envelope genes. J Virol 73 7 (1999) 5527-5534
38. Lyons A., Kanesa-thasan N., Kuschner R.A., Eckels K.H., Putnak R., Sun W., et al. A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis. Vaccine 25 17 (2007) 3445-3453